Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
Fact checked by Jonah Feldman
Publication
Article
Peers & Perspectives in OncologyJune I 2025
Volume 3
Pages: 84
In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
CASE SUMMARY
- A 59-year-old postmenopausal woman presented with a newly discovered lump in her left breast and palpable axillary lymph node (ALN).
- Imaging identified an 8.1-cm solid mass in the lower inner quadrant with a suspicious ALN.
- Core biopsy: positive for invasive ductal carcinoma (IDC), estrogen receptor, 80%; progesterone receptor, 30%; HER2 0 by immunohistochemistry; grade 2
- Fine-needle aspiration of ALN was positive for IDC.
- Germline testing was negative for deleterious mutations.
- Staging PET/CT was negative for distant metastasis.
- The patient received neoadjuvant doxorubicin, cyclophosphamide, and paclitaxel.
- She underwent bilateral mastectomy.
- Pathology (left breast): 5.1-cm IDC and 1/15 positive nodes
- Her 21-gene assay recurrence score: 24
- Anatomic stage: pT3 pN1a M0/stage IIIA
Articles in this issue
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
Peers Weigh Efficacy vs Toxicity of Nirogacestat in Progressive Desmoid Tumors
Daud Evaluates Checkpoint Inhibitors in Advanced and Earlier Stages of cSCC
Evaluating Neoadjuvant and Adjuvant Therapies and Benefits for MIBC
Renshaw Discusses Addition of Anti-CD20 and BTK/BCL2 Combinations in CLL
Tarhini Breaks Down RELATIVITY-047 Survival Benefits and PFS2
Evaluating Role of Loncastuximab in Third-Line DLBCL After CAR T
Third-Line DLBCL Therapy Choice Depends on Access to Bispecifics
Comparing Melanoma Immunotherapy Outcomes in Key Clinical Trials
Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin
Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC
Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant
Comparing VEGF TKI/IO Vs IO/IO Combination Efficacy in Metastatic RCC
Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition
Disease Site and Access Factor into Selection of GVHD Therapy
Recent Videos
Related Content
